Combination Antifungal Therapy

  • Elizabeth Dodds AshleyEmail author
  • Melissa D. Johnson


Invasive fungal infections continue to cause significant morbidity and mortality among hospitalized patients. In particular, recent studies indicate an increase in the incidence of mould infections among transplant recipients, and Candida species have risen to be the third most common pathogen isolated among intensive care unit patients [1, 2]. Advances in modern medical treatment have led to growth in the at-risk population for fungal infections [3]. For example, Cryptococcus neoformans has re-emerged as a growing cause of invasive fungal disease due in large part to the development of novel immune therapy for malignancies, rheumatologic disorders, and management of rejection in transplant populations [4]. Unfortunately, these infections are associated with failures and high rates of relapse even when patients receive recommended therapy [5, 6]. Treatment of invasive mycoses continues to be challenging and complicated by the net state of immunosuppression among infected hosts combined with relative lack of efficacy, significant toxicity, drug–drug interactions, and drug resistance associated with available antifungal agents.


Antifungal Agent Invasive Aspergillosis Invasive Fungal Infection Invasive Candidiasis Cryptococcal Meningitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–17.PubMedGoogle Scholar
  2. 2.
    Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis. 2005;41:521–6.PubMedGoogle Scholar
  3. 3.
    Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother. 2005;56:5–11.Google Scholar
  4. 4.
    Chayakulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin North Am. 2006;20:507–44.PubMedGoogle Scholar
  5. 5.
    Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis. 2006;43:1060–8.PubMedGoogle Scholar
  6. 6.
    Perfect JR. Management of cryptococcosis: how are we doing? PLoS Med. 2007;4:e47.PubMedGoogle Scholar
  7. 7.
    Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother. 2004;48:693–715.Google Scholar
  8. 8.
    Johnson MD, Perfect JR. Combination antifungal therapy: what can and should we expect? Bone Marrow Transplant. 2007;40:297–306.PubMedGoogle Scholar
  9. 9.
    Ostrosky-Zeichner L. Combination antifungal therapy: a critical review of the evidence. Clin Microbiol Infect. 2008;14 Suppl 4:65–70.PubMedGoogle Scholar
  10. 10.
    Lewis RE, Kontoyiannis DP. Rationale for combination antifungal therapy. Pharmacother. 2001;21:149S–64.Google Scholar
  11. 11.
    Vazquez JA. Clinical practice: combination antifungal therapy for mold infections: much ado about nothing? Clin Infect Dis. 2008;46:1889–901.PubMedGoogle Scholar
  12. 12.
    Baddley JW, Pappas PG. Antifungal combination therapy: clinical potential. Drugs. 2005;65:1461–80.PubMedGoogle Scholar
  13. 13.
    Vermes A, Guchelaar H-J, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000;46:171–9.PubMedGoogle Scholar
  14. 14.
    Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science. 2005;309:2185–9.PubMedGoogle Scholar
  15. 15.
    Cowen LE, Singh SD, Köhler JR, et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci. 2009;106:2818–23.PubMedGoogle Scholar
  16. 16.
    Imhof A, Schaer DJ, Schwarz U, Schanz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly. 2006;136:739–42.Google Scholar
  17. 17.
    Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563–71.PubMedGoogle Scholar
  18. 18.
    Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med. 2001;111:528–34.PubMedGoogle Scholar
  19. 19.
    van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. 1997;337:15–21.PubMedGoogle Scholar
  20. 20.
    Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med. 1979;301:126–31.PubMedGoogle Scholar
  21. 21.
    Alexander BD, Dodds Ashley ES, Addison RM, Alspaugh JA, Chao NJ, Perfect JR. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2006;8:13–20.PubMedGoogle Scholar
  22. 22.
    Dodds Ashley ES, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis. 2006;43:S28–S39.Google Scholar
  23. 23.
    Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis. 2003;37:188–224.Google Scholar
  24. 24.
    Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004;363:1764–7.PubMedGoogle Scholar
  25. 25.
    Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003;36:1221–8.PubMedGoogle Scholar
  26. 26.
    Kennedy MS, Deeg HJ, Siegel M, Crowley JJ, Storb R, Thomas ED. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation. 1983;35:211–5.PubMedGoogle Scholar
  27. 27.
    Shaukat A, Benekli M, Vladutiu GD, Slack JL, Wetzler M, Baer MR. Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother. 2003;37:1032–5.PubMedGoogle Scholar
  28. 28.
    Stone JA, Migoya EM, Hickey L, et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother. 2004;48:4306–14.PubMedGoogle Scholar
  29. 29.
    Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26:1730–44.PubMedGoogle Scholar
  30. 30.
    Rex JH, Walsh TJ, Nettleman M, et al. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis. 2001;33:95–106.PubMedGoogle Scholar
  31. 31.
    Polak A. The past, present and future of antimycotic combination therapy. Mycoses. 1999;42:355–70.PubMedGoogle Scholar
  32. 32.
    Mukherjee PK, Sheehan DJ, Hitchcock CA, et al. Combination treatment of invasive fungal infections. Clin Microbiol Rev. 2005;18:163–94.PubMedGoogle Scholar
  33. 33.
    Rodriguez MM, Calvo E, Serena C, Marine M, Pastor FJ, Guarro J. Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob Agents Chemother. 2009;53:2153–5.PubMedGoogle Scholar
  34. 34.
    Ibrahim AS, Gebremariam T, Schwartz JA, Edwards Jr JE, Spellberg B. Posaconazole mono-or combination therapy for the treatment of murine zygomycosis. Antimicrob Agents Chemother. 2009; 53:772–5.PubMedGoogle Scholar
  35. 35.
    Ibrahim AS, Gebremariam T, Fu Y, Edwards JE Jr, Spellberg B. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008;52:1556–8.PubMedGoogle Scholar
  36. 36.
    Spellberg B, Fu Y, Edwards JE, Jr Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005;49:830–2.PubMedGoogle Scholar
  37. 37.
    Guembe M, Guinea J, Pelaez T, Torres-Narbona M, Bouza E. Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. Antimicrob Agent Chemother. 2007;51:3457–8.Google Scholar
  38. 38.
    Rodriguez MM, Serena C, Marine M, et al. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother. 2008;52:3786–8.PubMedGoogle Scholar
  39. 39.
    Hamilton JD, Elliott DM. Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice. J Infect Dis. 1975;131:129–37.PubMedGoogle Scholar
  40. 40.
    Block ER, Bennett JE. The combined effect of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis. Proc Soc Exp Bio Med. 1973;142:476–80.Google Scholar
  41. 41.
    Allendoerfer R, Marquis AJ, Rinaldi MG, Graybill JR. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother. 1991;35:726–9.PubMedGoogle Scholar
  42. 42.
    Pappas PG, Chetchotisakd P, Larsen RA, et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2009;48:1775–83.PubMedGoogle Scholar
  43. 43.
    Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis. 2008;47:123–30.PubMedGoogle Scholar
  44. 44.
    Powderly WG. Dosing amphotericin B in cryptococcal meningitis. Clin Infect Dis. 2008;47:131–2.PubMedGoogle Scholar
  45. 45.
    Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious Diseases Society of America. Clin Infect Dis 2010;50:291–322.PubMedGoogle Scholar
  46. 46.
    Pai MP, Samples ML, Mercier RC, et al. Activities and ultrastructural effects of antifungal combinations against simulated Candida endocardial vegetations. Antimicrob Agents Chemother. 2008;52:2367–76.PubMedGoogle Scholar
  47. 47.
    Karlowsky JA, Hoban DJ, Zhanel GG, Goldstein BP. In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. Int J Antimicrob Agents. 2006;27:174–7.PubMedGoogle Scholar
  48. 48.
    Baltch AL, Bopp LH, Smith RP, Ritz WJ, Michelsen PB. Anticandidal effects of voriconazole and caspofungin, singly and in combination, against Candida glabrata, extracellularly and intracellularly in granulocyte-macrophage colony stimulating factor (GM-CSF)-activated human monocytes. J Antimicrob Chemother. 2008;62:1285–90.PubMedGoogle Scholar
  49. 49.
    Barchiesi F, Spreghini E, Tomassetti S, Giannini D, Scalise G. Caspofungin in combination with amphotericin B against Candida parapsilosis. Antimicrob Agents Chemother. 2007;51:941–5.PubMedGoogle Scholar
  50. 50.
    Serena C, Marine M, Quindos G, et al. In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp. Antimicrob Agents Chemother. 2008;52:1529–32.PubMedGoogle Scholar
  51. 51.
    Tunger O, Bayram H, Degerli K, Dinc G, Cetin BC. Comparison of the efficacy of combination and monotherapy with caspofungin and liposomal amphotericin B against invasive candidiasis. Saudi Med J. 2008;29:728–33.PubMedGoogle Scholar
  52. 52.
    Cao B, Tsang PW, Tsang DN, Samaranayake LP, Wang J. A disc plate assay for characterization of the effect of interaction between polyenes and azoles on growth of Candida albicans CA12. Microbios. 1996;87:161–7.PubMedGoogle Scholar
  53. 53.
    Lewis RE, Lund BC, Klepser ME, Ernst EJ, Pfaller MA. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob Agents Chemother. 1998;42:1382–6.PubMedGoogle Scholar
  54. 54.
    Louie A, Liu W, Miller DA, et al. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Antimicrob Agents Chemother. 1999;43:2831–40.PubMedGoogle Scholar
  55. 55.
    Sugar AM, Liu X-P. Interactions of itraconazole with amphotericin B in the treatment of murine invasive candidiasis. J Infect Dis. 1998;177:1660–3.PubMedGoogle Scholar
  56. 56.
    Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35.PubMedGoogle Scholar
  57. 57.
    Steinbach WJ, Perfect JR, Cabell CH, et al. A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infect. 2005;51:230–47.PubMedGoogle Scholar
  58. 58.
    Lye DCB, Hughes A, O’Brien D, Athan E. Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review. Eur J Clin Microbiol Infect Dis. 2005;24:753–5.PubMedGoogle Scholar
  59. 59.
    Lopez-Ciudad V, Castro-Orjales MJ, Leon C, et al Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole. BMC Infect Dis. 2006;6:73.PubMedGoogle Scholar
  60. 60.
    Falcone M, Barzaghi N, Carosi G, et al. Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine. 2009;88:160–8.PubMedGoogle Scholar
  61. 61.
    Talarmin JP, Boutoille D, Tattevin P, et al. Candida endocarditis: role of new antifungal agents. Mycoses. 2009;52:60–6.PubMedGoogle Scholar
  62. 62.
    Demchok JP, Meletiadis J, Roilides E, Walsh TJ. Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp. Mycoses 2010;53;239–45.Google Scholar
  63. 63.
    Petraitis V, Petraitiene R, Hope WW, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother. 2009;53:2382–91.PubMedGoogle Scholar
  64. 64.
    Ryder NS, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol. 2001;39:91–5.PubMedGoogle Scholar
  65. 65.
    Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98:292–9.PubMedGoogle Scholar
  66. 66.
    Kontoyiannis DP, Ratanatharathorn V, Young JA, et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis. 2009;11:89–93.PubMedGoogle Scholar
  67. 67.
    Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39:797–802.PubMedGoogle Scholar
  68. 68.
    Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer. 2006;107:2888–97.PubMedGoogle Scholar
  69. 69.
    Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation. 2006;81:320–6.PubMedGoogle Scholar
  70. 70.
    Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006;53:337–49.PubMedGoogle Scholar
  71. 71.
    Schaffner A, Böhler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses. 1993;36:421–4.PubMedGoogle Scholar
  72. 72.
    Bajjoka IE, Bailey EM, Vazquez JA, Abouljoud MS. Combination antifungal therapy for invasive aspergillosis infection in liver transplant recipients: report of two patients. Pharmacother. 1999;19:118–23.Google Scholar
  73. 73.
    Kontoyiannis DP, Boktour M, Hanna H, et al. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer. 2005;103:2334–7.PubMedGoogle Scholar
  74. 74.
    Caillot D, Thiébaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies. Cancer. 2007;110:2740–6.PubMedGoogle Scholar
  75. 75.
    Thomas A, Korb V, Guillemain R, et al. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis. J Clin Pharm 2010;35:49–53.Google Scholar
  76. 76.
    Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–60.PubMedGoogle Scholar
  77. 77.
    Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother. 2002;46:245–7.PubMedGoogle Scholar
  78. 78.
    Ortoneda M, Capilla J, Pujol I, et al. Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans. J Antimicrob Chemother. 2002;49:525–9.PubMedGoogle Scholar
  79. 79.
    Dannaoui E, Afeltra J, Meis J, Verweij PE. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother. 2002;46:2708–11.PubMedGoogle Scholar
  80. 80.
    Gómez-López A, Cuenca-Estrella M, Mellado E, Rodríguez-Tudela JL. In vitro evaluation of combination of terbinafine with itraconazole or amphotericin B against Zygomycota. Diagn Microbiol Infect Dis. 2003;45:199–202.PubMedGoogle Scholar
  81. 81.
    Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007;117:2649–57.PubMedGoogle Scholar
  82. 82.
    Spellberg B, Walsh TJ, Kontoyiannis DP, et al. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009;48:1743–51.PubMedGoogle Scholar
  83. 83.
    Rothe A, Seibold M, Hoppe TH, et al. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol. 2004;83:394–7.PubMedGoogle Scholar
  84. 84.
    Makowsky MJ, Warkentin DI, Savoie ML. Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia. Ann Pharmacother. 2005;39:1365–6.PubMedGoogle Scholar
  85. 85.
    Steinbach WJ, Schell WA, Miller JL, Perfect JR. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol. 2003;41:3981–5.PubMedGoogle Scholar
  86. 86.
    Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis. 2003;22:111–3.PubMedGoogle Scholar
  87. 87.
    Gosbell IB, Toumasatos V, Yong J, Kuo RS, Ellis DH, Perrie RC. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses. 2003;46:233–6.Google Scholar
  88. 88.
    Rickerts V, Atta J, Herrmann S, et al. Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia. Mycoses. 2006;49:27–30.PubMedGoogle Scholar
  89. 89.
    Gonzalez CE, Couriel DR, Walsh TJ. Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis. 1997;24:192–6.PubMedGoogle Scholar
  90. 90.
    Reed C, Bryant R, Ibrahim AS, et al. Combination polyene caspofungin for treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47:364–71.PubMedGoogle Scholar
  91. 91.
    Spellberg B, Andes D, Perez M, et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother. 2009;53:3122–5.PubMedGoogle Scholar
  92. 92.
    Soummer A, Mathonnet A, Scatton O, et al. Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis. Antimicrob Agents Chemother. 2008;52:1585–6.PubMedGoogle Scholar
  93. 93.
    Sugar AM, Liu X-P. Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles. Antimicrob Agents Chemother. 2000;44:2004–6.PubMedGoogle Scholar
  94. 94.
    Steinbach WJ, Schell WA, Blankenship JR, Onyewu C, Heitman J, Perfect JR. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother. 2004;48:1664–9.PubMedGoogle Scholar
  95. 95.
    Blankenship JR, Steinbach WJ, Perfect JR, Heitman J. Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. Curr Opin Investig Drugs. 2003;4:192–9.PubMedGoogle Scholar
  96. 96.
    Chin NX, Weitzman I, Della-Latta P. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother. 1997;41:850–2.PubMedGoogle Scholar
  97. 97.
    Onyewu C, Blankenship JR, Del Poeta M, Heitman J. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother. 2003;47:956–64.PubMedGoogle Scholar
  98. 98.
    Sugar AM, Liu XP, Chen RJ. Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs. Antimicrob Agents Chemother. 1997;41:2518–21.PubMedGoogle Scholar
  99. 99.
    Scott EM, Tariq VN, McCrory RM. Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro. Antimicrob Agents Chemother. 1995;39:2610–4.PubMedGoogle Scholar
  100. 100.
    Yücesoy M, ÖKtem IM, Gülay Z. In-vitro synergistic effect of fluconazole with nonsteroidal anti-inflammatory agents against Candida albicans strains. J Chemother. 2000;12:385–9.PubMedGoogle Scholar
  101. 101.
    Quan H, Cao YY, Xu Z, et al. Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole. Antimicrob Agents Chemother. 2006;50:1096–9.PubMedGoogle Scholar
  102. 102.
    Han Y, Lee JH. Berberine synergy with amphotericin B against disseminated candidiasis in mice. Biol Pharm Bull. 2005;28:541–4.PubMedGoogle Scholar
  103. 103.
    Nakajima R, Kitamura A, Someya K, Tanaka M, Sato K. In vitro and in vivo antifungal activities of DU-6859a, a fluoro­quinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Antimicrob Agents Chemother. 1995;39:1517–21.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.School of Medicine and DentistryUniversity of Rochester Medical CenterRochesterUSA

Personalised recommendations